Profiling target engagement and cellular uptake of cRGD-decorated clinical-stage core-crosslinked polymeric micelles

Federica De Lorenzi, Larissa Yokota Rizzo, Rasika Daware, Alessandro Motta, Maike Baues, Matthias Bartneck, Michael Vogt, Marc van Zandvoort, Leonard Kaps, Qizhi Hu, Marielle Thewissen, Luca Casettari, Cristianne J F Rijcken, Fabian Kiessling, Alexandros Marios Sofias, Twan Lammers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Polymeric micelles are increasingly explored for tumor-targeted drug delivery. CriPec® technology enables the generation of core-crosslinked polymeric micelles (CCPMs) based on thermosensitive (mPEG-b-pHPMAmLacn) block copolymers, with high drug loading capacity, tailorable size, and controlled drug release kinetics. In this study, we decorated clinical-stage CCPM with the αvβ3 integrin-targeted cyclic arginine-glycine-aspartic acid (cRGD) peptide, which is one of the most well-known active targeting ligands evaluated preclinically and clinically. Using a panel of cell lines with different expression levels of the αvβ3 integrin receptor and exploring both static and dynamic incubation conditions, we studied the benefit of decorating CCPM with different densities of cRGD. We show that incubation time and temperature, as well as the expression levels of αvβ3 integrin by target cells, positively influence cRGD-CCPM uptake, as demonstated by immunofluorescence staining and fluorescence microscopy. We demonstrate that even very low decoration densities (i.e., 1 mol % cRGD) result in increased engagement and uptake by target cells as compared to peptide-free control CCPM, and that high cRGD decoration densities do not result in a proportional increase in internalization. In this context, it should be kept in mind that a more extensive presence of targeting ligands on the surface of nanomedicines may affect their pharmacokinetic and biodistribution profile. Thus, we suggest a relatively low cRGD decoration density as most suitable for in vivo application.

Original languageEnglish
Pages (from-to)1195-1211
Number of pages17
JournalDrug Delivery and Translational Research
Volume13
Issue number5
Early online date11 Jul 2022
DOIs
Publication statusPublished - May 2023

Keywords

  • BIODISTRIBUTION
  • COMPLETE REGRESSION
  • Core-crosslinked polymeric micelles
  • CriPec (R)
  • Cyclic arginine-glycine-aspartic acid (cRGD)
  • DELIVERY
  • IN-VIVO
  • INTEGRINS
  • Nanomedicine
  • Nanoparticles
  • RGD PEPTIDE
  • SILICA NANOPARTICLES
  • THERAPEUTICS
  • THERAPY
  • TUMOR ANGIOGENESIS
  • Tumor targeting

Cite this